Waystar shares slip in Nasdaq debut after digital health company priced IPO in middle of range

Waystar shares slip in Nasdaq debut after digital health company priced IPO in middle of range


Waystar CEO: We're building a visible, recurring revenue business driving profitable growth

Waystar shares slid about 3% in their Nasdaq debut on Friday, after the health-care payment software vendor priced its IPO in the middle of the expected range.

The stock opened at $21 per share, below the IPO price of $21.50 late Thursday. Waystar said its expected price would be between $20 and $23 per share in May. Shares closed down more than 3% to $20.70 on Friday.

The IPO market has been largely dormant since late 2021 when the extended bull market turned and investors began to worry about a weakening economy. Few technology companies have been willing to try and go public since then, and no digital health companies had a public exit in 2023, according to a report from Rock Health.

But the broader venture-backed tech market may be beginning to thaw. Social media platform Reddit, data center connectivity chip vendor Astera Labs and data software management maker Rubrik have all gone public this year. Health tech company Tempus AI has also issued a preliminary prospectus this year.

Based on Waystar’s initial share price, the company’s market cap is about $3.5 billion. The stock is trading under the ticker symbol “WAY.”

Waystar offers health-care payment and revenue cycle management tools and facilitates more than 5 billion payment transactions annually, according to its prospectus. The company was formed in 2017 after the health-care payment companies Navicure and ZirMed merged.

“We’re excited about the opportunity to be a public company because we think it helps us with awareness, helps us with credibility, helps us improve our capital structure and allows for further investments in areas such as generative AI,” Waystar CEO Matt Hawkins told CNBC’s “The Exchange” Friday.

For the quarter ending March 31, Waystar generated revenue of $224.8 million, up 18% from $191.1 million in the same period last year. Waystar reported a net loss of $15.9 million for the quarter compared with $10.6 million a year ago.

The company said it plans to use the money from the offering to pay off existing debt. JPMorgan Chase, Goldman Sachs and Barclays are leading the offering.

WATCH: Tech IPOs face hurdle

Startup valuations' impact on IPOs



Source

Healthy Returns: What to know about the FDA’s plan to speed up some drug reviews
Health

Healthy Returns: What to know about the FDA’s plan to speed up some drug reviews

FILE PHOTO: The headquarters of the U.S. Food and Drug Administration (FDA) is seen in Silver Spring, Maryland November 4, 2009.  Jason Reed | Reuters A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. The Food […]

Read More
Taking on Goliath: Brain surgeon’s clash with UnitedHealthcare shows insurer’s hardball tactics
Health

Taking on Goliath: Brain surgeon’s clash with UnitedHealthcare shows insurer’s hardball tactics

Dr. Catherine Mazzola, a pediatric neurosurgeon, runs a practice she says is in serious jeopardy because of recent moves by UnitedHealth Group. Zach Gross for NBC News Dr. Catherine Mazzola, a pediatric neurosurgeon, runs a practice in New Jersey that treats low-income children on Medicaid. Since 2008, she has cared for boys and girls with cerebral palsy, […]

Read More
FDA approves Gilead’s twice-yearly HIV prevention injection, offering a powerful and convenient new option
Health

FDA approves Gilead’s twice-yearly HIV prevention injection, offering a powerful and convenient new option

The logo of Gilead Sciences pharmaceutical company is seen in Oceanside, California, April 29, 2020. Mike Blake | Reuters The Food and Drug Administration on Wednesday approved Gilead’s twice-yearly antiviral injection for preventing HIV – a milestone that the company and some experts say could help bring the world closer to ending the decades-long epidemic […]

Read More